Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients

Valerie Speirs, Carmel Malone, David S. Walton, Michael J. Kerin, Stephen Atkin

Research output: Contribution to journalArticle

200 Citations (Scopus)

Abstract

Tamoxifen is currently the first-line therapy for treatment of hormone- dependent breast cancer. However, despite initial benefits, most patients eventually relapse. Two groups of patients were identified: (a) a tamoxifen- sensitive group (n = 8); and (b) a tamoxifen-resistant group (n = 9). Using reverse transcription-PCR, the relative expression of mRNA for both estrogen receptor (ER) β and transforming growth factor β1 was determined in each patient group and quantified against a known reference standard. ER-β mRNA was significantly up-regulated in the tamoxifen-resistant group as compared with the tamoxifen-sensitive group (P = 0.001 by Fisher's exact test), and, consistent with previous findings, transforming growth factor β1 was also up-regulated in the tamoxifen-resistant cohort (P = 0.02). The importance of ER-β in tamoxifen resistance was validated using tamoxifen-sensitive and - resistant cell lines, in which it was demonstrated that ER-β mRNA was significantly up-regulated in the resistant cells. These results lend further support to a role for ER-β as a poor prognostic factor in breast cancer.

Original languageEnglish
Pages (from-to)5421-5424
Number of pages4
JournalCancer Research
Volume59
Issue number21
Publication statusPublished - 1 Nov 1999
Externally publishedYes

Fingerprint

Tamoxifen
Estrogen Receptors
Breast Neoplasms
Messenger RNA
Transforming Growth Factors
Reverse Transcription
Hormones
Recurrence
Cell Line
Polymerase Chain Reaction
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Speirs, V., Malone, C., Walton, D. S., Kerin, M. J., & Atkin, S. (1999). Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients. Cancer Research, 59(21), 5421-5424.

Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients. / Speirs, Valerie; Malone, Carmel; Walton, David S.; Kerin, Michael J.; Atkin, Stephen.

In: Cancer Research, Vol. 59, No. 21, 01.11.1999, p. 5421-5424.

Research output: Contribution to journalArticle

Speirs, V, Malone, C, Walton, DS, Kerin, MJ & Atkin, S 1999, 'Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients', Cancer Research, vol. 59, no. 21, pp. 5421-5424.
Speirs, Valerie ; Malone, Carmel ; Walton, David S. ; Kerin, Michael J. ; Atkin, Stephen. / Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients. In: Cancer Research. 1999 ; Vol. 59, No. 21. pp. 5421-5424.
@article{7383014d593b47aaac0297d9b302fdc6,
title = "Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients",
abstract = "Tamoxifen is currently the first-line therapy for treatment of hormone- dependent breast cancer. However, despite initial benefits, most patients eventually relapse. Two groups of patients were identified: (a) a tamoxifen- sensitive group (n = 8); and (b) a tamoxifen-resistant group (n = 9). Using reverse transcription-PCR, the relative expression of mRNA for both estrogen receptor (ER) β and transforming growth factor β1 was determined in each patient group and quantified against a known reference standard. ER-β mRNA was significantly up-regulated in the tamoxifen-resistant group as compared with the tamoxifen-sensitive group (P = 0.001 by Fisher's exact test), and, consistent with previous findings, transforming growth factor β1 was also up-regulated in the tamoxifen-resistant cohort (P = 0.02). The importance of ER-β in tamoxifen resistance was validated using tamoxifen-sensitive and - resistant cell lines, in which it was demonstrated that ER-β mRNA was significantly up-regulated in the resistant cells. These results lend further support to a role for ER-β as a poor prognostic factor in breast cancer.",
author = "Valerie Speirs and Carmel Malone and Walton, {David S.} and Kerin, {Michael J.} and Stephen Atkin",
year = "1999",
month = "11",
day = "1",
language = "English",
volume = "59",
pages = "5421--5424",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients

AU - Speirs, Valerie

AU - Malone, Carmel

AU - Walton, David S.

AU - Kerin, Michael J.

AU - Atkin, Stephen

PY - 1999/11/1

Y1 - 1999/11/1

N2 - Tamoxifen is currently the first-line therapy for treatment of hormone- dependent breast cancer. However, despite initial benefits, most patients eventually relapse. Two groups of patients were identified: (a) a tamoxifen- sensitive group (n = 8); and (b) a tamoxifen-resistant group (n = 9). Using reverse transcription-PCR, the relative expression of mRNA for both estrogen receptor (ER) β and transforming growth factor β1 was determined in each patient group and quantified against a known reference standard. ER-β mRNA was significantly up-regulated in the tamoxifen-resistant group as compared with the tamoxifen-sensitive group (P = 0.001 by Fisher's exact test), and, consistent with previous findings, transforming growth factor β1 was also up-regulated in the tamoxifen-resistant cohort (P = 0.02). The importance of ER-β in tamoxifen resistance was validated using tamoxifen-sensitive and - resistant cell lines, in which it was demonstrated that ER-β mRNA was significantly up-regulated in the resistant cells. These results lend further support to a role for ER-β as a poor prognostic factor in breast cancer.

AB - Tamoxifen is currently the first-line therapy for treatment of hormone- dependent breast cancer. However, despite initial benefits, most patients eventually relapse. Two groups of patients were identified: (a) a tamoxifen- sensitive group (n = 8); and (b) a tamoxifen-resistant group (n = 9). Using reverse transcription-PCR, the relative expression of mRNA for both estrogen receptor (ER) β and transforming growth factor β1 was determined in each patient group and quantified against a known reference standard. ER-β mRNA was significantly up-regulated in the tamoxifen-resistant group as compared with the tamoxifen-sensitive group (P = 0.001 by Fisher's exact test), and, consistent with previous findings, transforming growth factor β1 was also up-regulated in the tamoxifen-resistant cohort (P = 0.02). The importance of ER-β in tamoxifen resistance was validated using tamoxifen-sensitive and - resistant cell lines, in which it was demonstrated that ER-β mRNA was significantly up-regulated in the resistant cells. These results lend further support to a role for ER-β as a poor prognostic factor in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0033231027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033231027&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 5421

EP - 5424

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 21

ER -